Most people are familiar with A, B, AB and O blood types, but there are hundreds of additional blood group “antigens” on red blood cells – substances that can trigger the body’s immune response – that differ from person to person. Each year, up to 16 deaths reported to the Federal Drug Administration are attributed to mismatches in red blood cell antigens that are not related to differences in A, B and O blood groups. Currently, no method is available that can determine all blood antigens. But as whole genome sequencing becomes routine for patients, it may be possible to modernize therapy by identifying both rare donors and at-risk recipients before blood transfusions.
In a new study, investigators from Brigham and Women’s Hospital and Harvard Medical School, as well as from the New York Blood Center have leveraged the MedSeq Project – the first randomized trial of whole genome sequencing in healthy adults – to develop and validate a computer program that can comprehensively and cost-effectively determine differences in individuals’ blood types with more than 99 percent accuracy. The team’s results are reported in The Lancet Haematology.
“Blood transfusion complications are common in patients needing chronic transfusion, but with current technology it is not cost effective to do blood typing for all antigens,” said first author William Lane, MD, PhD, director of Clinical Laboratory Informatics and assistant director of the Tissue Typing Laboratory in the BWH Department of Pathology. “But the algorithm we have developed can be applied to type everyone for all relevant blood groups at a low cost once sequencing is obtained.”
Blood transfusions are one of the most common procedures in medicine with more than 11 million units of blood transfused in the U.S. each year. Complications from blood transfusions can be life-threatening. When the body encounters foreign antigens on the donor cells, it can stimulate production of antibodies that can destroy the transfused donor cells. From birth, people have antibodies unique to their ABO blood type, but other antibodies against specific blood antigens can be stimulated during pregnancy from exposure to fetal cells or exposure to donor cells when receiving multiple blood transfusions.
“This approach has the potential to be one of the first routine clinical uses of genomics for medical care for patients needing blood transfusion,” said co-first author Connie M. Westhoff, PhD, at the New York Blood Center. “It could prevent serious or even fatal complications because once patients are sensitized they have a life-long risk of hemolytic transfusion reactions if blood transfusion is needed in an emergency.”
Today, most testing for blood donors and patients include only ABO and Rh matching, but more than 300 red blood cell antigens and 33 platelet antigens are known. To create a way to cost-effectively type many people for these antigens, Lane teamed up with scientists directing the MedSeq Project and experts in blood group genetics at the New York Blood Center to build a database and develop a computer software algorithm, known as bloodTyper, that could rapidly and accurately predict an individual’s blood group antigen profile from genomic sequences. Lane, Westhoff and colleagues validated the software by comparing it to traditional, and more labor-intensive, methods. bloodTyper was more than 99 percent accurate when typing from the MedSeq Project participants’ genomes. Lane notes that this work would not have been possible without access to samples from the MedSeq Project, and close collaboration with MedSeq’s principal investigator, Robert Green, MD, MPH, and co-investigator, Heidi Rehm, PhD.
“This report demonstrates a previously unanticipated use case and benefit that will accrue as whole genome sequencing become a routine part of medical care,” said Green, one of the senior authors on the study, director of the Genomes2People Research Program at BWH and professor of medicine at Harvard Medical School. “Genome sequencing can now identify potential transfusion recipients who need rare blood types and the individuals who can safely provide them.”
The Latest on: Whole genome sequencing
via Google News
The Latest on: Whole genome sequencing
- No Omicron case detected in latest genome sequencing –DOHon December 8, 2021 at 10:26 pm
The Department of Health (DOH) reported on Thursday that no case of Omicron COVID-19 variant was detected from the latest whole genome sequencing conducted.
- PacBio and UCLA Health Announce Research Collaboration for Whole Genome Sequencing in Rare Diseaseson December 7, 2021 at 7:38 am
Collaboration aims to identify variants not easily detectible by short-read sequencing, increasing diagnostic yield in rare disease patientsMENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- PacBio ...
- The Future of Health: Genome Sequencing by David Priede, PhDon December 6, 2021 at 11:13 am
There hasn’t been a pharmaceutical developed in the last 20 years that hasn’t utilized genome information. The impact of genome sequencing (reading DNA) will provide vast advancements in the future of ...
- Software optimizations make variant calling 8 to 16 times faster for genome sequencingon December 3, 2021 at 4:33 am
The cost of sequencing has gone down tremendously. But still it is not used in daily practice. One of the reasons for this is that the processing of the raw data into useful insights takes a long time ...
- Sacramento County now able to use in-house genome sequencing to track omicron varianton December 2, 2021 at 10:34 am
During a public health briefing Thursday, Sacramento County's public health officer Dr. Olivia Kasirye said the county now has the capability to do whole genome sequencing, allowing them to better ...
- What are pros and cons of whole-genome sequencing for every UK baby?on December 2, 2021 at 8:49 am
Knowing a baby’s whole genetic code would help detect a range of health problems, but would not replace need for some existing tests ...
- Scientists raise concerns over UK baby genome sequencing planon December 2, 2021 at 7:45 am
Exclusive: experts say scheme seems designed to create valuable dataset rather than improve screening ...
- Worldwide Whole Genome and Exome Sequencing Industry to 2026 - Featuring 10x Genomics, Abbott Diagnostics and Agilent Among Otherson December 2, 2021 at 6:15 am
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct ...
- Outlook on the Whole Genome and Exome Sequencing Global Market to 2026 - Key Drivers and Challengeson December 1, 2021 at 1:48 am
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis - 2022 to 2026 " report has been added to ...
via Bing News